Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14408233 | 0.93 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CNAAACYP3A4 | |
| SCHEMBL13540552 | 0.93 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CNAAACYP3A4 | |
| SCHEMBL13051894 | 0.93 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CNAAACYP3A4 | |
| SCHEMBL13509140 | 0.92 | ADRB3 (0.47) | ADRB3ADRA2BADRA2CNAAACYP3A4 | |
| SCHEMBL7924768 | 0.91 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL10254433 | 0.91 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13886255 | 0.90 | ADRB3 (0.53) | ADRB3ADRA2BADRA2CNAAACYP3A4 | |
| SCHEMBL13026168 | 0.86 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CNAAACYP3A4 | |
| SCHEMBL13892482 | 0.86 | ADRB3 (0.50) | ADRB3ADRA2BADRA2CCYP3A4TSHR | |
| SCHEMBL14001907 | 0.85 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CNAAACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662779-B2 | Triazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090047248-A1 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047248-A1 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, CTSC | ADRB3 4473/4885ADRA2B 4662/4885ADRA2C 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.